Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) has scheduled its virtual 2020 Annual Meeting of Stockholders for June 10, 2020, at 9:00 a.m. Eastern Time. Stockholders can attend online using a control number found in proxy materials. Paratek focuses on developing life-saving therapies, with its lead product NUZYRA® for treating bacterial infections. The company is collaborating with Zai Lab for NUZYRA® in China and holds rights to SEYSARA® for moderate to severe acne, licensed to Almirall. Paratek received a BARDA contract in 2019 to develop NUZYRA® for pulmonary anthrax.
- Scheduled virtual 2020 Annual Meeting on June 10, 2020.
- Lead product NUZYRA® treats life-threatening bacterial infections.
- Collaboration with Zai Lab expands market reach for NUZYRA® in China.
- Secured a contract from BARDA for NUZYRA® development for pulmonary anthrax.
- None.
BOSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced its virtual 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will now be held at 9:00 a.m. Eastern Time.
The previously announced date of the Annual Meeting, June 10, 2020, will not change. As described in the proxy materials previously distributed for the Annual Meeting, stockholders as of the close of business on April 13, 2020, the record date, may attend the meeting virtually via the Internet at www.virtualshareholdermeeting.com/PRTK2020 by entering the 16-digit control number found in such proxy materials or, for stockholders that hold their shares in “street name,” by following the instructions provided by each such stockholder’s bank or brokerage firm. Online check-in will begin at 8:45 a.m. Eastern Time, and stockholders should allow ample time for the check-in procedures.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
The Company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC (Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world.
In 2019, Paratek was awarded a contract from BARDA to support the development of NUZYRA for the treatment of pulmonary anthrax.
For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.
Forward Looking Statements
This press release contains forward-looking statements including statements related to our overall strategy, products, prospects and potential. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.
| CONTACT: | ||
| Investor and Media Relations: | ||
| Ben Strain | ||
| 617-807-6688 | ||
| ir@ParatekPharma.com |
FAQ
When is the Paratek Pharmaceuticals Annual Meeting in 2020?
How can stockholders attend the Paratek Pharmaceuticals Annual Meeting?
What is NUZYRA® and what is its purpose?
What partnership does Paratek Pharmaceuticals have regarding NUZYRA®?
What contract did Paratek Pharmaceuticals secure in 2019?
